Weight of polyethylene wear particles is similar in TKAs with oxidized zirconium and cobalt-chrome prostheses

使用氧化锆和钴铬合金假体的全膝关节置换术中,聚乙烯磨损颗粒的重量相似。

阅读:1

Abstract

BACKGROUND: The greater lubricity and resistance to scratching of oxidized zirconium femoral components are expected to result in less polyethylene wear than cobalt-chrome femoral components. QUESTIONS/PURPOSES: We examined polyethylene wear particles in synovial fluid and compared the weight, size (equivalent circle diameter), and shape (aspect ratio) of polyethylene wear particles in knees with an oxidized zirconium femoral component with those in knees with a cobalt-chrome femoral component. PATIENTS AND METHODS: One hundred patients received an oxidized zirconium femoral component in one knee and a cobalt-chrome femoral component in the other. There were 73 women and 27 men with a mean age of 55.6 years (range, 44-60 years). The minimum followup was 5 years (mean, 5.5 years; range, 5-6 years). Polyethylene wear particles were analyzed using thermogravimetric methods and scanning electron microscopy. RESULTS: The weight of polyethylene wear particles produced at the bearing surface was 0.0223 +/- 0.0054 g in 1 g synovial fluid in patients with an oxidized zirconium femoral component and 0.0228 +/- 0.0062 g in patients with a cobalt-chrome femoral component. Size and shape of polyethylene wear particles were 0.59 +/- 0.05 microm and 1.21 +/- 0.24, respectively, in the patients with an oxidized zirconium femoral component and 0.52 +/- 0.03 microm and 1.27 +/- 0.31, respectively, in the patients with a cobalt-chrome femoral component. Knee Society knee and function scores, radiographic results, and complication rate were similar between the knees with an oxidized zirconium and cobalt-chrome femoral component. CONCLUSIONS: The weight, size, and shape of polyethylene wear particles were similar in the knees with an oxidized zirconium and a cobalt-chrome femoral component. We found the theoretical advantages of this surface did not provide the actual advantage. LEVEL OF EVIDENCE: Level I, therapeutic study. See the guidelines for Authors for a complete description of levels of evidence.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。